Abstract:Large tumor suppressor (Lats) plays a critical role in maintaining cellular homeostasis and is the core to mediate Hippo growth-inhibitory signaling pathway. SUMOylation is a reversible and dynamic process that regulates a variety of cell functions. Here, we show that SUMOylation of Lats1 affects its kinase activity specifically towards Hippo signaling. Small ubiquitin-like modifier (SUMO) 1 interacts with and directly SUMOylates Lats1, whereas loss of SUMOylation pathway function disrupts Lats1 SUMOylation. Among potential SUMOylation sites on hLats1, K751 and K830 are conversed and essential for maintaining the transcriptional output of Hippo signaling, whereas K751 mutation more significantly abolishes SUMO1-induced Lats1 SUMOylation than K830 mutation. Though Lats1 SUMOylation at K751 affects neither its subcellular distribution nor its interactions with YAP and TAZ, it significantly destabilizes the phosphorylated Lats1 (Thr1079 but not Ser909), resulting in the attenuation of Lats1 kinase activity and inhibition of Hippo signaling. Moreover, HepG2 hepatocellular carcinoma cells express significantly more SUMOylated Lats1 than LO2 normal human hepatic cells, and in HepG2 cells or HepG2 cells xenografts, Lats1 SUMOylation at K751 consistently attenuates Lats1 kinase activity and subsequently suppresses Hippo signaling, resulting in not only the promotion of cell proliferation and colony formation but also the suppression of cell apoptosis. Together, we demonstrate that Lats1 SUMOylation at K751 suppresses its kinase activity and subsequently attenuates its tumor-suppressor functions. Thus, this study provides additional insight into how Hippo signaling is regulated and highlights the potentially critical role of Lats1 SUMOylation in tumor development.

TAB2, an Important Upstream Adaptor of Interleukin-1 Signaling Pathway, is Subject to SUMOylation.

Regulation of IL-4-induced STAT6 activation by SUMOylation (P6307)

Regulation of TAK–TAB Complex Activation Through Ubiquitylation

SUMOylation Attenuates Human Β-Arrestin 2 Inhibition of IL-1R/TRAF6 Signaling.

SUMO modification regulates the transcriptional activity of XBP1.

SUMOylation Activates Large Tumour Suppressor 1 to Maintain the Tissue Homeostasis During Hippo Signalling

SUMOylation of Large Tumor Suppressor 1 at Lys751 Attenuates Its Kinase Activity and Tumor-Suppressor Functions

SUMO Modification Reverses Inhibitory Effects of Smad Nuclear Interacting Protein-1 in TGF-β Responses*

Sumoylation Enhances the Activity of the TGF-β/SMAD and HIF-1 Signaling Pathways in Keloids

TAB2 Scaffolds TAK1 and NLK in Repressing Canonical Wnt Signaling

Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 gamma 2, an inhibitor of TGF-beta signaling.

SUMOylation of the polycomb group protein L3MBTL2 facilitates repression of its target genes

Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 gamma 2, an inhibitor of TGF-β signaling

Activation of Transforming Growth Factor-β Signaling by SUMO-1 Modification of Tumor Suppressor Smad4/DPC4*

TAK1-TABs Complex: A Central Signalosome in Inflammatory Responses

Functional Proteomics Study Reveals SUMOylation of TFII-I is Involved in Liver Cancer Cell Proliferation

Monoclonal antibody-based systematic identification of SUMO1-modification sites reveals TFII-I SUMOylation is involved in tumor growth

TCR-Induced Tyrosine Phosphorylation at Tyr270 of SUMO Protease SENP1 by Lck Modulates SENP1 Enzyme Activity and Specificity

Sumo-1/Ubc9 Promotes Nuclear Accumulation And Metabolic Stability Of Tumor Suppressor Smad4

TAK1-binding protein 2 (TAB2) and TAB3 are redundantly required for TLR-induced cytokine production in macrophages

Regulation of Smad Functions Through Ubiquitination and Sumoylation Pathways